Clinical Data

Austin – November 04, 2026 -- Genprex, Inc. (NASDAQ: GNPX) reported that low TROP2 expression was consistently associated with primary resistance to its lead gene therapy Reqorsa (quaratusugene ozeplasmid) across multiple preclinical non-small cell lung cancer (NSCLC) models. The company says the finding could guide patient selection in future trials.

About half of tested NSCLC models showed primary resistance

Approximately 50% of 10 NSCLC cell lines and 50% of 12 patient-derived organoid models showed primary resistance to TUSC2 gene delivery. Protein-expression analyses identified low TROP2 expression as a marker associated with that resistance.

Patient biopsies from a TUSC2 trial back the association

Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial supported the link between TROP2 expression and treatment response. The company did not disclose patient numbers or effect sizes.

PHILADELPHIA – – November 04, 2026 -- Verismo Therapeutics' CD19-targeted KIR-CAR T therapy SynKIR-310 produced an 80% objective response rate (4 of 5 evaluable patients) in relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), with no cytokine release syndrome (CRS) or neurotoxicity (ICANS) of any grade. The data come from the first two dose cohorts of the Phase 1 CELESTIAL-301 trial (NCT06544265). The company will present updated results as an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting.

SynKIR-310 delivers 60% complete response rate and no dose-limiting toxicities in early cohorts

Across dose cohorts 1 and 2, the complete response rate was 60%. Median duration of response in complete responders has not been reached, and one patient remained in complete response at the 12-month assessment.

CRANFORD, N.J. – November 05, 2026 -- Citius Oncology (Nasdaq: CTOR) reported that 13 of 41 heavily pretreated cutaneous T-cell lymphoma (CTCL) patients with significant itch (32%; 95% CI, 18.1–48.1) achieved a clinically meaningful itch reduction on LYMPHIR (denileukin diftitox-cxdl) in the pivotal Study 302. The health-related quality of life (HRQoL) data were presented orally by Christiane Querfeld, MD, PhD, of City of Hope at the EORTC-CLTG 2026 Annual Meeting in Berlin, held October 8–10, 2026.

Responders show Skindex-29 improvement of up to 13.69 points

Among 25 responders in the primary analysis set (Stage I–III, n=69), the mean change from baseline in Skindex-29 Total Score ranged from −5.38 to −13.69 points across assessments. Lower scores indicate better quality of life. Non-responders showed slightly positive to near-zero changes.

Binyamina – November 05, 2026 -- OncoHost's 22-protein plasma signature detected acquired immunotherapy resistance in advanced non-small cell lung cancer (NSCLC) a median of 170 days, about 5.6 months, before radiologic progression, according to data the company will present at the International Society of Liquid Biopsy (ISLB) meeting in Madrid on November 7-9.

Two-cohort study analyzes 440 serial plasma samples from 109 patients

The abstract, titled "Longitudinal plasma proteomic profiling predicts immunotherapy response dynamics and overall survival (OS) in NSCLC," validates the signature as a tool for tracking treatment response over time. Researchers analyzed 440 serial plasma samples from 109 patients across two independent cohorts. Patients received immune checkpoint inhibitor (ICI) monotherapy, ICI plus chemotherapy, or dual ICI therapy.

Philadelphia – November 03, 2026 -- Verismo Therapeutics' SynKIR-110 achieved the fastest tumor control among three CAR T designs in preclinical mesothelioma models while producing roughly 10-fold less IFNγ and 30-fold less TNFα and IL-2 than a CD28-based single-chain CAR T.

The company will present the data at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in Phoenix (Abstract 253). The study compared SynKIR-110 with CD28- and 4-1BB-based single-chain CAR T cells in mesothelioma xenograft models.

SynKIR-110 shows lower exhaustion markers than both single-chain comparators

Tumor-infiltrating SynKIR-110 CD8 T cells expressed fewer of the exhaustion markers TIM3, LAG3 and PD1 than cells from either single-chain design. In vitro data also showed reductions in T cell exhaustion, off-target proliferation and toxicity.

Stockholm – November 03, 2026 -- Sobi (STO: SOBI) will present six abstracts on two late-stage gout assets, pozdeutinurad (AR882) and nanoencapsulated sirolimus plus pegadricase (NASP), at ACR Convergence 2026, the American College of Rheumatology annual meeting, in Orlando, Florida, on 6–11 November 2026.

Phase 3 REDUCE-2 results for pozdeutinurad headline the program

The presentations include results from the Phase 3 REDUCE-2 study of pozdeutinurad, an investigational once-daily oral, highly selective URAT1 inhibitor for uncontrolled gout. REDUCE-2 is one of two 12-month, randomised, double-blind, placebo-controlled Phase 3 studies, alongside REDUCE-1, that are evaluating the drug in more than 800 patients. Both trials assess its ability to lower serum urate (SU) in patients with uncontrolled gout.

Earlier Phase 2 studies showed a sustained SU reduction, dissolution of tophi and a generally well-tolerated safety profile, according to Sobi.

Burlington – November 03, 2026 -- PAQ Therapeutics will present the first clinical data for PT0253, its selective KRAS G12D degrader, in a late-breaking oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain, on November 20.

Phase 1 data in advanced solid tumors will cover safety and antitumor activity

The presentation reports findings from the company's ongoing Phase 1 trial in patients with advanced solid tumors. The abstract title (6LBA) describes a differentiated safety profile and antitumor activity for PT0253, including in patients who received prior (K)RAS-targeted therapy.

The slot is scheduled for 12:36-12:44 p.m. CET in Plenary Session 6, "Proffered Papers: Advances in Targeting RAS." ENA 2026 runs November 18-20.

RALEIGH – November 02, 2026 -- RedHill Biopharma (NASDAQ: RDHL) said two independent in vitro studies confirmed that its Crohn's disease candidate RHB-204 kills Mycobacterium avium subspecies paratuberculosis (MAP) at a level comparable to RHB-104, which posted a 64% efficacy gain in a Phase 3 trial.

Two microbiology centers confirm MAP-killing in culture and phage assays

The studies used long-term intracellular culture and spot and phage assays. One was led by Professor Tim Bull of City St George's University of London. The other was led by Professor Irene Grant of Queen's University Belfast and Dr Hannah Dane, working with Rapid-myco Technologies.

ABBOTT PARK, Ill. – November 02, 2026 -- Abbott's investigational Amulet 360 left atrial appendage (LAA) occluder achieved complete closure (zero mm leak) in 96.3% of patients assessed by transesophageal echocardiography (TEE) at one year in the VERITAS pivotal study.

Abbott (NYSE: ABT) presented the data in a late-breaking session at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego on Nov. 1, 2026. The results were published simultaneously in JACC: Cardiovascular Interventions. The device targets people with non-valvular atrial fibrillation (AFib) who may need an alternative to long-term blood-thinning medication.

VERITAS one-year data show stroke-free rates above 98%

More than 98% of patients remained free from ischemic stroke or systemic embolism through one year. More than 98% were free from cardiovascular-related mortality.

SCOTTSDALE, Ariz. – October 30, 2026 -- LifeStance Health (Nasdaq: LFST) reports that 74% of its patients with treatment-resistant depression achieved a clinically meaningful reduction in symptoms after 12 weeks of esketamine (Spravato), while 61% of TMS patients improved after at least 30 sessions. The outpatient mental healthcare provider is expanding access to both specialty services across the U.S.

Esketamine analysis covers 258 patients and shows suicidal ideation falling to 2%

LifeStance tracked progress with the Patient Health Questionnaire (PHQ-9). It defines clinically meaningful improvement as a score reduction of five or more points.

Among the 258 esketamine patients, the share reporting suicidal ideation nearly every day fell from 13% before treatment to 2% afterward, an 85% reduction.